Turning cold tumors hot: from molecular mechanisms to clinical applications
J Zhang, D Huang, PE Saw, E Song - Trends in immunology, 2022 - cell.com
Immune checkpoint blockade (ICB) therapies have achieved clinical benefit, but most
'immune-cold'solid tumors are not responsive. The diversity of immune evasion mechanisms …
'immune-cold'solid tumors are not responsive. The diversity of immune evasion mechanisms …
Exploring immunotherapy in colorectal cancer
J Weng, S Li, Z Zhu, Q Liu, R Zhang, Y Yang… - Journal of hematology & …, 2022 - Springer
Chemotherapy combined with or without targeted therapy is the fundamental treatment for
metastatic colorectal cancer (mCRC). Due to the adverse effects of chemotherapeutic drugs …
metastatic colorectal cancer (mCRC). Due to the adverse effects of chemotherapeutic drugs …
[HTML][HTML] Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion
Immune checkpoint blockade, which blocks inhibitory signals of T cell activation, has shown
tremendous success in treating cancer, although success still remains limited to a fraction of …
tremendous success in treating cancer, although success still remains limited to a fraction of …
Cancer immune evasion through loss of MHC class I antigen presentation
K Dhatchinamoorthy, JD Colbert, KL Rock - Frontiers in immunology, 2021 - frontiersin.org
Major histocompatibility class I (MHC I) molecules bind peptides derived from a cell's
expressed genes and then transport and display this antigenic information on the cell …
expressed genes and then transport and display this antigenic information on the cell …
Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL
WH Wilson, GW Wright, B Hodkinson… - Cancer cell, 2021 - cell.com
In diffuse large B cell lymphoma (DLBCL), tumors belonging to the ABC but not GCB gene
expression subgroup rely upon chronic active B cell receptor signaling for viability, a …
expression subgroup rely upon chronic active B cell receptor signaling for viability, a …
[HTML][HTML] Targeting the epigenetic regulation of antitumour immunity
Dysregulation of the epigenome drives aberrant transcriptional programmes that promote
cancer onset and progression. Although defective gene regulation often affects oncogenic …
cancer onset and progression. Although defective gene regulation often affects oncogenic …
A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications
GW Wright, JD Phelan, ZA Coulibaly, S Roulland… - Cancer cell, 2020 - cell.com
The development of precision medicine approaches for diffuse large B cell lymphoma
(DLBCL) is confounded by its pronounced genetic, phenotypic, and clinical heterogeneity …
(DLBCL) is confounded by its pronounced genetic, phenotypic, and clinical heterogeneity …
Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes
Triple-negative breast cancer (TNBC) is a collection of biologically diverse cancers
characterized by distinct transcriptional patterns, biology, and immune composition. TNBCs …
characterized by distinct transcriptional patterns, biology, and immune composition. TNBCs …
[HTML][HTML] EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis
Canonically, EZH2 serves as the catalytic subunit of PRC2, which mediates H3K27me3
deposition and transcriptional repression. Here, we report that in acute leukaemias, EZH2 …
deposition and transcriptional repression. Here, we report that in acute leukaemias, EZH2 …
Epigenetic therapies for cancer
SE Bates - New England Journal of Medicine, 2020 - Mass Medical Soc
Epigenetic Therapies for Cancer | New England Journal of Medicine Skip to main content The
New England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES …
New England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES …